/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Cingulate Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$3.87 0.0154(1.54%) CING at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 3.88
Highest Today 3.95
Today’s Open 3.89
Prev. Close 3.89
52 Week High 6.01
52 Week Low 3.20
Day’s Range: Low 3.88 High 3.95
52-Week Range: Low 3.20 High 6.01
1 day return -
1 Week return +5.14
1 month return +4.86
3 month return +3.46
6 month return -8.49
1 year return -7.94
3 year return -80.6
5 year return -
10 year return -

Institutional Holdings

Commonwealth Equity Services Inc 2.18

Vanguard Group Inc 0.64

Susquehanna International Group, LLP 0.60

Geode Capital Management, LLC 0.58

Vanguard Institutional Extnd Mkt Idx Tr 0.50

Fidelity Extended Market Index 0.40

Virtu Financial LLC 0.24

UBS Group AG 0.23

LPL Financial Corp 0.22

XTX Topco Ltd 0.20

Bank of America Corp 0.14

Fidelity Total Market Index 0.12

Spartan Extended Market Index Pool F 0.11

Fidelity Series Total Market Index 0.09

NT Ext Equity Mkt Idx Fd - NL 0.09

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.07

Northern Trust Extended Eq Market Idx 0.06

NT Ext Equity Mkt Idx Fd - L 0.06

Spartan Total Market Index Pool G 0.05

Tower Research Capital LLC 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Citigroup Inc 0.01

SBI Securities Co Ltd 0.00

Advisor Group Holdings, Inc. 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Market Status

Strong Buy: 1

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 26.29 M

PB Ratio 6.9833

PE Ratio 0.0

Enterprise Value 22.72 M

Total Assets 14.86 M

Volume 85023

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-21205277 -21.2M, FY22:-17850232 -17.9M, FY21:-20740493 -20.7M, FY20:-7283867 -7.3M, FY19:-11445336 -11.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-106782 -0.1M, Q2/2025:-146989 -0.1M, Q1/2025:-165291 -0.2M, Q3/2024:-3282087000 -3282.1M, Q2/2024:-3206180000 -3206.2M

Quarterly Net worth Q3/2025:-7341062 -7.3M, Q2/2025:-4788735 -4.8M, Q1/2025:-3802691 -3.8M, Q3/2024:-3231604000 -3231.6M, Q2/2024:-3209677 -3.2M

Fund house & investment objective

Company Information Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Organisation Biotechnology

Employees 13

Industry Biotechnology

CEO Dr. Shane J. Schaffer Pharm.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow